Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip

Reuters05-08

May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories

reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.

The supplier of laboratory apparatus and instruments for drug manufacturers and biotech companies continues to see adjusted revenue growth for the full-year between 1% and 2.5% on a currency-neutral basis.

Large rival Thermo Fisher Scientific slightly bumped up its annual profit forecast in April while Waters Corp left its outlook for the year unchanged as it remains cautious about a recovery in its key markets.

Subdued spending in the biotech sector as well as sluggish demand in the key China market has hit Bio-Rad's life sciences segment sales, offset by an increase in demand for its clinical diagnostics products.

The Hercules, California-based company continues to be cautiously optimistic about a gradual recovery in the biopharma market in the second half of the year.

Sales from its life sciences unit, which makes products for biotech, pharmaceutical and food testing clients, fell 25.3% to $241.7 million.

On an adjusted basis, Bio-Rad recorded a per-share profit of $2.29 for the quarter ended March 31, marginally above analysts' estimate of $2.15.

Shares of the company fell 1.4% to $276 in after market hours.

(Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona and Shailesh Kuber)

((Unnamalai.L@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433765755?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-08 06:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2433765755","market":"sh","top_or_hot":-1,"title":"Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip","media":"Reuters","content":"<html><body><p>May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories</p><p>  reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.</p><p>   The supplier of laboratory apparatus and instruments for drug manufacturers and biotech companies continues to see adjusted revenue growth for the full-year between 1% and 2.5% on a currency-neutral basis.</p><p>   Large rival Thermo Fisher Scientific    slightly bumped up its annual profit forecast in April while Waters Corp    left its outlook for the year unchanged as it remains cautious about a recovery in its key markets.</p><p>   Subdued spending in the biotech sector as well as sluggish demand in the key China market has hit Bio-Rad's life sciences segment sales, offset by an increase in demand for its clinical diagnostics products.</p><p>   The Hercules, California-based company continues to be cautiously optimistic about a gradual recovery in the biopharma market in the second half of the year.</p><p>   Sales from its life sciences unit, which makes products for biotech, pharmaceutical and food testing clients, fell 25.3% to $241.7 million.</p><p>   On an adjusted basis, Bio-Rad recorded a per-share profit of $2.29 for the quarter ended March 31, marginally above analysts' estimate of $2.15.</p><p>   Shares of the company fell 1.4% to $276 in after market hours.</p><p> (Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona and Shailesh Kuber)</p><p>((Unnamalai.L@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-08 06:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories  reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China. ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIO","symbol_name":"Bio Rad实验室","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2433765755","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433765755","pubTimestamp":1715119733,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories  reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIO":"Bio Rad实验室"},"translate_title":"Bio-Rad实验室重申2024年收入增长前景；股票滑坡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIO":0.9},"content_text":"May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories  reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.   The supplier of laboratory apparatus and instruments for drug manufacturers and biotech companies continues to see adjusted revenue growth for the full-year between 1% and 2.5% on a currency-neutral basis.   Large rival Thermo Fisher Scientific    slightly bumped up its annual profit forecast in April while Waters Corp    left its outlook for the year unchanged as it remains cautious about a recovery in its key markets.   Subdued spending in the biotech sector as well as sluggish demand in the key China market has hit Bio-Rad's life sciences segment sales, offset by an increase in demand for its clinical diagnostics products.   The Hercules, California-based company continues to be cautiously optimistic about a gradual recovery in the biopharma market in the second half of the year.   Sales from its life sciences unit, which makes products for biotech, pharmaceutical and food testing clients, fell 25.3% to $241.7 million.   On an adjusted basis, Bio-Rad recorded a per-share profit of $2.29 for the quarter ended March 31, marginally above analysts' estimate of $2.15.   Shares of the company fell 1.4% to $276 in after market hours. (Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona and Shailesh Kuber)((Unnamalai.L@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433765755"}